These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28678009)

  • 1. [Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.].
    Vozmediano-Chicharro R; Blasco Hernández P; Madurga-Patuel B
    Arch Esp Urol; 2017 Jul; 70(6):561-569. PubMed ID: 28678009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.].
    Merino Salas S
    Arch Esp Urol; 2018 Jun; 71(5):502-505. PubMed ID: 29889041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of oxybutynin in transdermal patches for treating overactive bladder.
    Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
    Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.
    Aaron LE; Morris TJ; Jahshan P; Reiz JL
    Curr Med Res Opin; 2012 Aug; 28(8):1369-79. PubMed ID: 22769237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
    Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ
    J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High patient satisfaction with the transdermal system].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):27. PubMed ID: 23646401
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
    Akino H; Namiki M; Suzuki K; Fuse H; Kitagawa Y; Miyazawa K; Fujiuchi Y; Yokoyama O
    Int J Urol; 2014 Apr; 21(4):389-94. PubMed ID: 24118296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.
    Pizzi LT; Talati A; Gemmen E; Dahl NV; Bunz TJ; Sand PK
    Pharmacoeconomics; 2009; 27(4):329-39. PubMed ID: 19485428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin.
    Müller-Arteaga C; Batista-Miranda JE; Zubiaur Libano C; El Khoury Moreno R; Morales Solchaga G; Casas Nebra J; Leva Vallejo M; Gonzalez Garcia O; Errando-Smet C; Arlandis-Guzman S
    Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):143-150. PubMed ID: 30470585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
    Staskin DR; Rosenberg MT; Dahl NV; Polishuk PV; Zinner NR
    Int J Clin Pract; 2008 Jan; 62(1):27-38. PubMed ID: 17983434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MATRIX study: evaluating the data in older adults.
    Newman DK
    Director; 2008; 16(3):15-9. PubMed ID: 19343887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.